La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Gritstone bio Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Andrew Allen

Amministratore delegato

US$3.4m

Compenso totale

Percentuale dello stipendio del CEO	18.8%
Mandato del CEO	9yrs
Proprietà del CEO	1.5%
Durata media del management	3.4yrs
Durata media del Consiglio di amministrazione	6.6yrs

Aggiornamenti recenti sulla gestione

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Jun 11

Recent updates

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Jun 11

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Apr 07

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Aug 14

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Andrew Allen rispetto agli utili di Gritstone bio?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$133m
Mar 31 2024	n/a	n/a	-US$145m
Dec 31 2023	US$3m	US$646k	-US$138m
Sep 30 2023	n/a	n/a	-US$139m
Jun 30 2023	n/a	n/a	-US$130m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	US$3m	US$620k	-US$120m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$116m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	US$4m	US$589k	-US$75m
Sep 30 2021	n/a	n/a	-US$72m
Jun 30 2021	n/a	n/a	-US$70m
Mar 31 2021	n/a	n/a	-US$71m
Dec 31 2020	US$2m	US$569k	-US$105m
Sep 30 2020	n/a	n/a	-US$106m
Jun 30 2020	n/a	n/a	-US$107m
Mar 31 2020	n/a	n/a	-US$103m
Dec 31 2019	US$2m	US$533k	-US$94m
Sep 30 2019	n/a	n/a	-US$84m
Jun 30 2019	n/a	n/a	-US$75m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$2m	US$475k	-US$65m
Sep 30 2018	n/a	n/a	-US$65m
Jun 30 2018	n/a	n/a	-US$56m
Mar 31 2018	n/a	n/a	-US$47m
Dec 31 2017	US$592k	US$436k	-US$41m

Compensazione vs Mercato: La retribuzione totale di Andrew ($USD 3.44M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 680.04K ).

Compensazione vs guadagni: La retribuzione di Andrew è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Andrew Allen (58 yo)

9yrs

Mandato

US$3,444,071

Compensazione

Dr. Andrew R. Allen, BM, BCh, MA, MRCP, M.D., Ph D., serves as Independent Director at Verge Analytics, Inc. since September 2021. He has also held clinical development leadership positions at Chiron Corpo...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Andrew Allen	Co-Founder	9yrs	US$3.44m	1.53% $ 915.4k
Erin Jones	Executive VP & COO	3.4yrs	US$1.52m	0.063% $ 37.8k
Karin Jooss	Executive VP and Head of Research & Development	3.4yrs	US$1.58m	0.39% $ 232.9k
Vassiliki Economides	Executive VP & CFO	3.2yrs	Nessun dato	0.059% $ 35.2k
James Cho	Chief Accounting Officer	3.6yrs	Nessun dato	0.070% $ 41.8k
George MacDougall	Director of Investor Relations & Corporate Communications	no data	Nessun dato	Nessun dato
Stacy Proctor	Executive VP & Chief People Officer	3.1yrs	Nessun dato	Nessun dato
Matthew Hawryluk	Executive VP & Chief Business Officer	8.8yrs	Nessun dato	0.034% $ 20.3k

3.4yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di GRTS è considerato esperto (durata media dell'incarico 3.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Andrew Allen	Co-Founder	9yrs	US$3.44m	1.53% $ 915.4k
Elaine Jones	Independent Chairman of the Board	4.9yrs	US$176.00k	0% $ 0
Steve Krognes	Independent Director	6.1yrs	US$148.50k	0% $ 0
Lawrence Corey	Independent Director	2yrs	US$132.50k	0% $ 0
Timothy Chan	Member of Scientific Advisory Board	7.2yrs	Nessun dato	Nessun dato
Eugene Zhukovsky	Member of Scientific Advisory Board	5.3yrs	Nessun dato	0% $ 0
Graham Lord	Member of Scientific Advisory Board	7.2yrs	Nessun dato	Nessun dato
Naiyer Rizvi	Independent Director & Member of Scientific Advisory Board	8.2yrs	US$140.00k	0% $ 0
James Gulley	Member of Scientific Advisory Board	7.2yrs	Nessun dato	Nessun dato
Alessandro Sette	Member of Scientific Advisory Board	7.2yrs	Nessun dato	Nessun dato
Shefali Agarwal	Independent Director	3.2yrs	US$138.50k	0% $ 0
Clare Fisher	Independent Director	2.6yrs	US$136.50k	Nessun dato

6.6yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GRTS sono considerati esperti (durata media dell'incarico 6.6 anni).

Gritstone bio Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Consensus revenue estimates decrease by 60%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Price target decreased by 16% to US$4.33

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.30 loss in 1Q 2023)

Gritstone bio, Inc. to Report Q1, 2024 Results on May 09, 2024

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Consensus revenue estimates decrease by 17%, EPS upgraded

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform (SLATE)

New minor risk - Market cap size

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Gritstone bio, Inc. has completed a Follow-on Equity Offering in the amount of $32.5 million.

Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite

Consensus revenue estimates decrease by 37%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Price target decreased by 12% to US$8.80

Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial

Consensus revenue estimates fall by 40%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna (Samrna) Vaccine Candidates Against Covid-19 (Part of the Company’s Coral Program) at IDWeek 2023

Price target increased by 20% to US$10.34

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Price target increased by 20% to US$10.34

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Consensus revenue estimates fall by 53%

Price target decreased by 14% to US$8.60

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone bio, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.75

Gritstone bio, Inc. Announces Updated Overall Survival Results from Granite Phase 1/2 Study and Poster At Sitc 2022

Price target decreased to US$10.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$10.00

Gritstone bio, Inc. announced that it expects to receive $44.999991 million in funding from Redmile Group, LLC, Gilead Sciences, Inc., The Invus Group, LLC, Hercules Capital, Inc. and other investors

Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst

Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022

Gritstone reaches six-month high on publication of data for cancer vaccine

Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

Consensus revenue estimates increase by 14%

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Price target increased to US$16.00

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Gritstone bio announces $80M credit facility

Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Gritstone bio: Potential To Advance Colorectal Cancer Treatment

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Index

Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation

Gritstone Announces Results from Preclinical Study of Its Self-Amplifying Mrna (Samrna) Vaccine Against Sars-Cov-2 Published in Nature Communications

Gritstone Bio, Inc. Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of Granite and Trial in Progress Poster At Asco

Price target increased to US$16.00

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Gritstone bio, Inc. to Report Q1, 2022 Results on May 05, 2022

Price target decreased to US$14.67

Less than half of directors are independent

Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates

Consensus revenue estimates fall by 57%

Full year 2021 earnings: EPS misses analyst expectations

We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate

Gritstone: Why The Stock Fell On Positive Data

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)